Laekna announces first IND clearance by U.S. FDA for internally-discovered LAE102

SHANGHAI and WARREN, N.J. , May 21, 2023 /PRNewswire/ — Laekna, a clinical-stage biotechnology company dedicated to bringing novel therapies to cancer and liver fibrosis patients worldwide, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of LAE102 antibody to initiate clinical development. This is Laekna’s first … Read more